Wednesday, July 8, 2026

pharma · Renal Impairment · Urinary Tract Infection · SPRO

Spero Therapeutics

Spero Therapeutics patent portfolio — 16 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

675 Massachusetts Ave, 14th Floor, Cambridge, MA 02139, US HQ
2013 Founded
45 Employees
Public company Type
SPRO · NYSE Ticker
Company details
Status
Public
HQ
675 Massachusetts Ave, 14th Floor, Cambridge, MA 02139, US
Founded
2013
Employees
45
Programs
21
Drugs
9
Patents
16
Intelligence · Patents

Spero Therapeutics patents

16 pharmaceutical patents indexed for Spero Therapeutics. 0 expire within 24 months.

Spero Therapeutics has 16 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. US 12428395

    Heterocyclic compounds as kinase inhibitor and uses thereof

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12291548

    Compounds, compositions, and methods for the treatment of disease

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12226403

    Tebipenem pivoxil immediate and modified release oral dosage forms

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 12146004

    Polymyxin compounds and uses thereof

    Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 12098155

    Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 12048691

    High dosage tebipenem pivoxil tablet formulation

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11718621

    Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use

    Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11459357

    Polymyxin compounds

    Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 11180444

    Polyimino ketoaldehydes

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 11033569

    Compounds,Compositions, and methods for the treatment of disease

    Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 10889587

    Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 10793482

    Compounds and compositions for delivery of nutrients and micronutrients to plants

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 9937192

    Combination therapy to treat mycobacterium diseases

    Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 9604976

    Antibacterial compounds

    Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 9572809

    Combination therapy to treat Mycobacterium diseases

    Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 6593394

    Bioactive and osteoporotic bone cement

    Expires Mon Jul 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

How many patents does Spero Therapeutics have?

16 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Spero Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.